nonacog beta pegol: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
nonacog beta pegol: clinical details
Prescribing considerations
- Treatment should be supervised by a clinician experienced in haemophilia care.
- Consider medically observed initial administrations because factor IX products can cause hypersensitivity.
- Record product name and batch number for biological-product traceability.
- Assess benefit and thrombotic risk in liver disease, postoperative patients, neonates and people predisposed to thrombosis or disseminated intravascular coagulation.
Contraindications and cautions
- Hypersensitivity to nonacog beta pegol or any excipient.
- Known allergic reaction to hamster protein.
Monitoring
- Assess clinical control of bleeding and investigate an unexpectedly poor response.
- Monitor for neutralising factor IX inhibitors using an appropriate Bethesda-based method.
- Allergic reactions should prompt evaluation for an inhibitor.
- If factor IX measurement is needed, use a validated chromogenic assay or a qualified one-stage assay; many aPTT reagents produce misleading results and silica-based reagents should be avoided.
- Monitor clinically and biologically for thrombosis or consumptive coagulopathy in at-risk patients.
Clinical pharmacology
A recombinant human factor IX conjugated to a 40 kDa polyethylene glycol group on its activation peptide. Activation removes the pegylated peptide and leaves native activated factor IX, while pegylation extends the circulating half-life of the inactive molecule.
Formulation and product differences
- The selected product is a powder supplied with histidine solvent in a pre-filled syringe and a vial adapter.
- After reconstitution it forms an intravenous solution; only the supplied solvent should be used.
- The pack does not include the infusion set, alcohol swabs, gauze or plasters.
nonacog beta pegol preparations and strengths
Injection
Route: Parenteral
Strengths: 500 units, 1000 units, 2000 units, 3000 units
nonacog beta pegol interactions
No direct interactions between recombinant factor IX products and other medicines have been reported. However, medicines that impair clotting can worsen the underlying bleeding tendency, so new medicines should be checked with the haemophilia team.
Aspirin and non-steroidal anti-inflammatory medicines such as ibuprofen
These can increase bleeding risk and should not be taken unless the haemophilia team has specifically advised their use.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.